PF 07612577
Alternative Names: Ceftibuten + AVP; CTB + AVP; PF 06264006 + PF 07338233; PF-07612577Latest Information Update: 08 Feb 2024
At a glance
- Originator Pfizer
- Class Anti-infectives
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Urinary tract infections
Most Recent Events
- 08 Feb 2024 PF 07612577 receives Fast Track designation for Urinary tract infections [PO] (In volunteers) in USA, prior to February 2024 (Pfizer pipeline, February 2024)
- 23 Jun 2023 Pfizer completes a phase I trial for Urinary tract infections (In volunteers) in Belgium (NCT05554237)
- 07 Oct 2022 Phase-I clinical trials in Urinary tract infections in USA (unspecified route) (Pfizer pipeline, November 2022)